Five Minutes in Healthcare is where I discuss current events with some of the industry's most influential leaders.

Today I am joined by Jim Williams, head of the global Molecular Imaging business at Siemens Healthineers, for a discussion about the role of imaging in the new therapeutic drug treatments for Alzheimer’s disease. The conversation is timely, as the FDA recently approved the second major Alzheimer’s therapeutic drug, Eli Lilly's donanemab.

Jim and I previously talked about the rapid adoption of theranostics and where the next treatment breakthroughs might take place. I encourage you to check out that interview after you listen to this one.


We hope you enjoy the conversation. Please tell us what you think, and let us know who you would like to see interviewed next.